CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 164 filers reported holding CLOVIS ONCOLOGY INC in Q4 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $83,612 | -92.3% | 41,200 | -89.7% | 0.00% | -100.0% |
| Q4 2021 | $1,088,000 | -33.5% | 401,300 | +17.6% | 0.00% | -40.0% |
| Q4 2020 | $1,637,000 | -16.5% | 341,100 | +1.4% | 0.01% | -28.6% |
| Q3 2020 | $1,961,000 | -58.4% | 336,351 | -51.8% | 0.01% | -22.2% |
| Q2 2020 | $4,710,000 | +341.0% | 697,800 | +4344.6% | 0.01% | +125.0% |
| Q4 2017 | $1,068,000 | -63.4% | 15,700 | -55.6% | 0.00% | -69.2% |
| Q3 2017 | $2,917,000 | +72.8% | 35,400 | -26.6% | 0.01% | +85.7% |
| Q4 2015 | $1,688,000 | -32.8% | 48,230 | +76.5% | 0.01% | -30.0% |
| Q3 2015 | $2,513,000 | +50.0% | 27,330 | -8.7% | 0.01% | +42.9% |
| Q4 2014 | $1,675,000 | +30.6% | 29,919 | +5.8% | 0.01% | +40.0% |
| Q3 2014 | $1,283,000 | +8.8% | 28,283 | -0.6% | 0.01% | 0.0% |
| Q2 2014 | $1,179,000 | -42.5% | 28,465 | -3.9% | 0.01% | -44.4% |
| Q1 2014 | $2,051,000 | +21.2% | 29,610 | +5.5% | 0.01% | +12.5% |
| Q4 2013 | $1,692,000 | +4.4% | 28,068 | +5.2% | 0.01% | 0.0% |
| Q3 2013 | $1,621,000 | – | 26,672 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,997,826 | $10,834,000 | 0.69% |
| Ikarian Capital, LLC | 1,112,669 | $3,016,000 | 0.45% |
| Versant Venture Management, LLC | 101,855 | $276,000 | 0.15% |
| Virtus ETF Advisers LLC | 60,836 | $165,000 | 0.06% |
| EMFO, LLC | 21,500 | $58,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| PINNACLE ASSOCIATES LTD | 706,336 | $1,914,000 | 0.03% |
| XTX Topco Ltd | 20,920 | $57,000 | 0.03% |
| State of Wyoming | 25,419 | $69,000 | 0.03% |